Shane Lafayette

Shane Lafayette has extensive work experience in corporate development, finance, and strategic finance. Shane is currently employed at Centessa Pharmaceuticals as the Director of Corporate Development, a position they have held since August 2022. Prior to this role, they served as the Associate Director of Corporate Development at Centessa Pharmaceuticals from March 2021 to August 2022.

Before joining Centessa Pharmaceuticals, Shane worked at Arvelle Therapeutics as the Associate Director of Corporate Development from August 2020 to February 2021. Shane also served as the Manager of Finance & Commercial Strategy at Arvelle Therapeutics from September 2019 to August 2020.

From March 2019 to September 2019, Shane worked at Axovant Gene Therapies, Ltd as the Manager of Strategic Finance. Prior to this role, they worked as a Senior Financial Analyst at Axovant Gene Therapies, Ltd from January 2018 to March 2019.

Shane's earlier work experience includes a role as a Financial Analyst in FP&A at Bracco from June 2017 to December 2017. Shane also worked as a Financial Analyst at LifeCell, An Acelity Company from February 2015 to June 2017.

Overall, Shane has demonstrated a strong background in corporate development and finance, with progressively increasing roles and responsibilities throughout their career.

Shane Lafayette pursued an MBA, Master of Business Administration degree from NYU Stern School of Business during the years 2021 to 2023. Prior to that, they earned a BSBA degree in Finance from Thomas Edison State University. Shane began their educational journey at Raritan Valley Community College, where they completed an AS degree in Business Administration and Management, General.